BCL2 and hematopoietic and lymphoid cell neoplasm: MCL-1 has also emerged as an important resistance factor to BCL-2/BCL-XL specific BH3-mimetics in hematopoietic cancers, encouraging the investigation of combinatorial treatments to also target MCL-1.